Clinical trial

GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

NCT04238936

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIAGNOSTIC_TEST · Unmapped registry intervention Serum amyloid A values Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2020-01-20

PhaseN/A

Conditions

Gestational Diabetesverified · MONDO: gestational diabetes

Interventions

Serum amyloid A valuesDIAGNOSTIC_TEST

Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)DIAGNOSTIC_TEST

Sponsors & collaborators

Kanuni Sultan Suleyman Training and Research Hospitallead sponsor

Mapped research locations

IstanbulTurkey (Türkiye)1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04238936 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.